SecBot SecBot
SECBOTREPLAY Home › Report › PCRX

PCRX · Merger litigation disclosed

Pacira BioSciences, Inc. · SC 14D-9/A filed Nov 12, 2026 at 16:15 ET

At the news

NEUTRALIMPACT 3/10

SC 14D-9/A filed Nov 12, 2026 at 16:15 ET

Pacira BioSciences filed Amendment No. 2 to its Schedule 14D-9, updating the legal proceedings section to disclose that two stockholder lawsuits and fifteen demand letters have been filed challenging the adequacy of disclosures in the merger with Viatris. The board continues to recommend the $36.50 per share tender offer, and the Pacira defendants intend to vigorously defend the actions.

  • Two stockholder complaints filed in New York state court alleging omitted or misrepresented material information in the Schedule 14D-9 regarding the merger
  • Fifteen demand letters received, including two draft complaints, seeking additional disclosure
  • Pacira defendants have not been served with the complaints
  • Board continues to recommend the $36.50 per share cash tender offer by Viatris

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access